Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour
Authors:
- Alexandre ParienteAPAlexandre Pariente
- Francine EtcharryFEFrancine Etcharry
- Valérie CalesVCValérie Cales
- Yves LabordeYLYves Laborde
- Sylvie FerrariSFSylvie Ferrari
- Michel BiourMBMichel Biour
- 1 July 2006
- journal article
- case report
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 18 (7) , 785-787
Abstract
We report the first case of hepatocellular injury occurring in a patient treated for metastatic gastrointestinal stromal tumour (GIST) with imatinib mesylate, with two positive rechallenges including one with 2.5% of the current therapeutic dosage. The patient could be treated later with sunitinib without liver toxicity. Grade 3-4 liver toxicity could occur in one out of 40 treated patients with imatinib for GIST, and fatalities have been reported. Regular monitoring of liver function tests is essential in patients treated with imatinib.Keywords
This publication has 12 references indexed in Scilit:
- Hépatite aiguë cytolytique induite par l’imatinib mesylateGastroentérologie Clinique Et Biologique, 2004
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Fatal hepatic necrosis following imatinib mesylate therapyBlood, 2003
- Histological features of acute hepatitis after imatinib mesylate treatmentLeukemia, 2003
- Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitisLeukemia, 2002
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsNew England Journal of Medicine, 2002
- Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II studyBlood, 2002
- Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 studyBlood, 2002
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I studyThe Lancet, 2001